Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|MB-102||CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes|CD123 CAR-T||MB-102 is comprised of engineered T cells expressing chimeric antigen receptor consisting of CD123, CD28 fused to CD3 zeta, and a truncated EGFR (EGFRt), which may induce cytotoxic immune response against CD123-positive tumor cells (NCI Drug Dictionary).|
|Mesna||Mesnex||D-7093|UCB 398|MSA|mercaptoethane sulfonate|Mesnum|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 6||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04318678||Phase I||Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab||CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) ((CATCHAML))||Not yet recruiting|